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Angiogenesis is indispensable for solid tumor expansion, and thus it has become a 
major target of cancer research and anti-cancer therapies. Deciphering the arcane 
actions of various cell populations during tumor angiogenesis requires sophisticated 
research models, which could capture the dynamics and complexity of the process. 
There is a continuous need for improvement of existing research models, which 
engages interdisciplinary approaches of tissue engineering with life sciences. Tireless 
efforts to develop a new model to study tumor angiogenesis result in innovative 
solutions, which bring us one step closer to decipher the dubious nature of cancer. This 
review aims to overview the recent developments, current limitations and future 
challenges in three-dimensional tissue-engineered models for the study of tumor 
angiogenesis and for the purpose of elucidating novel targets aimed at anti-cancer drug 
discovery. 
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1 INTRODUCTION 
Angiogenesis, the formation of new blood vessels out of existing ones, is an essential 
prerequisite for tumor growth, progression and metastasis, and thus is a promising 
target for new therapeutic interventions. Tumor vascularization, known as “angiogenic 
switch”, occurs mainly via sprouting angiogenesis as a result of imbalanced expression 
and function of pro-angiogenic factors [1]. Angiogenic switch is a complex, multistep 
and dynamic process, which involves extracellular matrix (ECM) degradation as well as 
endothelial cell (EC) migration and proliferation. 
A solid tumor has an organized structure composed of parenchyma (neoplastic cells) 
surrounded by stroma [2]. Stroma consists of a cell mass (ECs, inflammatory cells and 
fibroblasts) surrounded by ECM rich in proteoglycans and glycosaminoglycans, 
interstitial collagens (primarily types I and III), fibrin and fibronectin (Figure 1) [3]. Both 
cellular and acellular components continuously affect each other, influencing and 
 determining the speed of tumor progression. The cycle of tumor growth and 
vascularization is propelled by the hypoxic center of the cancer mass where accelerated 
cell proliferation results in increased oxygen demand. As a consequence, low oxygen 
tension drives expression of proteins of the angiogenic cascade, including vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) [4]. The 
gradient of pro-angiogenic factors activates ECs and attracts them towards the tumor 
mass in order to form new capillaries, and subsequently deliver lacking nutrients and 
oxygen [5]. Vascularization is a limiting and indispensible step of solid tumor 
progression. The diameter of avascular tumors is determined by the diffusion limit of 
oxygen from the nearest blood vessels, which is in the order of 100–200 μm [6]. Solid 
tumors bigger than 1-2 mm3 require increased oxygen and nutrients supply [1, 7]. 
Therefore, tumor progression requires access to the vascular system and an increased 
blood supply in order to overcome size limitation and dormancy [6]. Moreover, the 
vascular density of tumors correlates with cancer prognosis and defines its stage of 
development [8]. Cancer vascularization follows stage- and tissue-specific regulatory 
mechanisms that control the induction of angiogenesis and cancer progression. 
However, more knowledge is required to effectively interfere with these mechanisms in 
order to identify new therapeutic strategies. For this, improved research models are 
needed to adequately reproduce the regulation of the cancer microenvironment during 
tumor angiogenesis, and thus provide better tools for developing novel anti-cancer 
compounds.  
  
Figure 1. Tumor microenvironment. The cellular compartment of the tumor (blue) is 
composed of immune cells, myofibroblasts, pericytes, endothelial cells and cancer cells. 
They contribute to tumor growth and progression by secretion of acellular components 
(green) such as growth factors, proteases and ECM proteins. Cell-cell and cell-ECM 
interactions establish a three-dimensional (3D) crosstalk network that contributes to 
tumor expansion.  
1.1 2D VS. 3D METHODOLOGY 
Over the years, scientists have developed an extensive range of experimental and 
integrative approaches to investigate the process of angiogenesis [9]. For example, 
conventional migration and proliferation assays, tubule formation assays, the Chick 
Chorioallantoic Membrane (CAM) assay, the corneal implant, aortic ring and many other 
methods have clearly enhanced the mechanistic understanding of blood vessel growth 
and function. Retrospectively, the majority of knowledge about both angiogenesis and 
cancer has been derived from conventional static two-dimensional (2D) cell culture 
systems. However, culture of cells on stiff and flat substrates such as tissue culture 
plastic or glass is a very simplified method of in vitro pre-clinical drug screening and 
 does not recapitulate the dynamic and highly complex tissue architectures [10] which 
may lead to a misleading results. For example, human ovarian cancer cells are less 
sensitive towards Taxol-induced apoptosis when grown in 3D as compared to 
monolayer culture indicating a distinct regulation of apoptotic mechanisms in 2D and 3D 
cultures [11]. 2D cell culture distorts cell-integrin and cell-cell interactions affecting gene 
and protein expression, cell proliferation and differentiation, and thus lacks physiological 
relevance [12, 13]. Moreover, 2D cell monolayers do not provide the geometrical and 
mechanical cues of tissues in vivo, and are therefore not suitable to accurately predict 
the responses of living organisms [14, 15]. As frequently reported in the literature, the 
most successful approach to limit cancer progression consists of  targeting cancer cells 
along with the surrounding stroma, which ultimately requires more complex research 
models [1].  
To address this challenge, a variety of biomimetic 3D vascular models have been 
developed over the last two decades, which have significantly contributed to the 
understanding of angiogenic processes and thus to the development of targeted anti-
angiogenic and anti-cancer compounds. Initially, simple vasculogenic assays based on 
collagen, introduced by Montesano et al. [16] and adapted by Davis et al. [17], became 
a landmark in the field motivating further research on EC morphogenesis as shown by 
George [18], West [19] or Gerecht [20]. On the other hand, research performed by 
Kamm [21], Munn [22-24], Stroock and Fischbach [25] [26] [27], Tien [28] and Chen [29] 
focused on engineered microfluidic approaches to study dynamic aspects of EC biology, 
angiogenesis and drug diffusion in vascular structures. The various published static and 
microfluidic culture platforms provided the ability to study how ECs sense and respond 
to mechanical stimuli and to seek new treatments for vascular diseases. Further 
development of these systems in conjunction with cancer research will allow for 
engineering improved tissue microenvironments for drug discovery and screening. 
Much progress has been also made in investigating the behavior of cancer tumors and 
their interactions with surrounding microenvironments in 3D compared with conventional 
2D models. This can be attributed to the fundamental work of the Bissell laboratory [30], 
who discovered strong phenotypic differences between normal and cancerous breast 
epithelial cells when grown in 3D instead of in 2D [31]. Epithelial carcinomas denote the 
 most common form of cancer [32]. The epithelium is distinguished by the formation of 
tightly ordered sheets of cells situated on top of a basement membrane, consisting 
mainly of collagen type IV and laminin, separating cells from the underlying stroma. 
Epithelial architecture is manifested in these specialized cell-cell and cell-matrix 
contacts, and ensures normal cell fate. Any change in microenvironmental conditions 
may disrupt this homeostasis and initiate tumor development and progression [33].  
Tumor modeling in 3D has already elucidated many differences in cancer progression 
previously unknown due to 2D culture methods. Perhaps most widely studied, 3D 
culture models of normal mammary glands [34] as well as breast carcinomas [35-38] 
have resulted in the study of genetic, phenotypic and proliferative variances between 2D 
and 3D breast cancer models. Prostate cancer cell migration, proliferation, spheroid 
formation and phenotype have also been investigated in 3D systems using Matrigel [39, 
40] or synthetic hydrogels [41]. Similar studies revealed differences in cell behavior 
between 2D and 3D models for the study of ovarian [42], lung [43] and colorectal cancer 
[44] biology and pathogenesis, thus raising fundamental questions about the validity of 
conventional 2D drug screening methods. As it is now widely accepted that the 
phenotype and method of cancer invasion is highly dependent on the structure, stiffness 
and density of the ECM, the use of 3D models of tumor invasion embody the 
microenvironment and behavior of tumors much more optimally than 2D monolayer 
cultures. Therefore, 3D tumor models are increasingly gaining interest for drug 
screening purposes in pre-clinical studies. 
While the functional role of cancer ECM has been extensively studied, much less is 
known about the role of the vascular component. The few existing reports are based on 
EC monoculture utilizing the addition of cancer-conditioned medium [45] or separating 
cancer from ECs by a membrane [46] or spatial arrangement [47]. However, these 
methods lack the 3D cell-ECM interactions that regulate EC capillary formation and 
invasiveness in vivo. On the other hand, various in vivo systems have been described to 
study angiogenesis and test potential therapeutic targets [48]. However, due to their 
complexity and heterogeneity, detailed interpretation of in vivo studies remains a 
challenge. Moreover, tumors in laboratory animal models develop often through 
temporally and histologically distinct steps underlining the differences in rodent and 
 human metabolism [1]. Thus, 3D cultures reproducing the phenotype of vascularized 
cancer tissue could represent a good alternative for in vivo experiments.  
Attempts to engineer 3D in vitro systems to mimic the complex tumor environment to 
offer a compromise between 2D cultures and animal studies were reviewed by  
Ghajar and Bissell [49] and Fischbach et al. [50]. In general, 3D in vitro culture systems 
have been recently recognized to more realistically reflect the in vivo response to 
therapeutic agents, and thus are expected to become useful for pre-clinical analyses 
[14, 51]. Therefore, the current challenge is to develop 3D models to study tumor 
angiogenesis, which could mimic the complexity of cancer-vasculature interactions by 
allowing for independent manipulation of its components. This can be achieved by 
utilizing tissue engineering tools which combine approaches from the fields of material 
science, chemistry, engineering, cell culture and modeling. 3D engineered tumor 
models could accelerate the dissection of mechanisms regulating the angiogenic 
sprouting process within the cancer microenvironment and advance the development of 
novel drugs against cancer.   
In the first section of this review, we present an overview of tissue engineered 
approaches used to study cancer and angiogenesis with an insight into vascular and 
cancer biomimetics. In the second part, we discuss biomaterial scaffolds as an 
indispensable tool to study tumor angiogenesis in vitro. The third section gives an 
overview of the existing in vitro models addressing tumor angiogenesis. Section four 
describes future research directions in various areas of tissue engineering required to 
build an ideal 3D model of tumor angiogenesis to serve as an anti-cancer drug 
screening platform. Finally, we summarize the achievements and indicate the 
prospective steps for the field. 
2 BIOMATERIALS 
3D tissue engineering approaches require utilization of suitable 3D scaffolds which 
mimic the ECM, enable spatial organization, and mechanical support for the cells. The 
materials have to be cytocompatible to allow for cell attachment, survival, expansion 
and differentiation. There are several types of scaffolds, both of natural and synthetic 
origin, which have been shown to direct both cancer and EC morphogenesis, and 
 angiogenesis in vitro [52-55]. Research based on natural scaffolds has demonstrated 
that the matrix plays a significant role in cancer pathogenesis by creating gradients of 
soluble factors, metabolites and oxygen [25, 47, 56]. Similarly, matrix properties control 
the process of angiogenic sprouting by guiding EC migration, proliferation and capillary 
formation [54]. Utilizing 3D matrices in order to study the dynamics of EC recruitment 
and growth of new vessels toward the tumor mass can greatly improve our 
understanding of tumor-driven angiogenesis and lead to the development of compounds 
which selectively fight cancer. For that, an engineered scaffold has to be designed in 
order to recapitulate the complex tumor microenvironment and at the same time to 
direct the multistep process of angiogenesis. The scaffold material has to provide 
simultaneously a variety of means such as (1) mechanical stability and elasticity for 3D 
cell support, (2) interconnected porosity and degradability for cell interaction, 
remodeling and diffusion of soluble factors, (3) presentation of adhesive ligands 
allowing for integrin activation and cell attachment and (4) storage of soluble factors to 
generate molecular gradients. Moreover, the material has to enable a flexible and 
independent adjustment of its properties in order to generate a variety of experimental 
conditions.  
The majority of 3D approaches have been developed utilizing the protein-based natural 
materials such as collagen type I, fibrin or laminin-rich basement membrane extract 
known as Matrigel due to their broad availability and the easiness of handling. 
Additionally, natural scaffolds carry a variety of intrinsic signals, which ensure an 
excellent cell survival rate and efficiently guide morphogenetic processes such as 
breast cancer morphogenesis [44], EC capillary morphogenesis [45], and sprouting [46]. 
Therefore, the behavior of cancer cells in natural 3D matrices may be closer to that 
displayed in vivo than in synthetic 3D matrices. Nevertheless, natural scaffolds have 
several drawbacks such as limited control over degradability, lack of mechanical 
stability and batch-to-batch variability, which can affect drug delivery and diffusion, and 
lead to irreproducible or misguided results. Therefore, recently there is a looming trend 
toward synthetic scaffolds, which offer several advantages such as easiness of 
chemical modifications, and tight control over the range of mechanical, and biochemical 
properties of the scaffolds.  
 There have been few reports detailing the use of synthetic materials to develop 3D 
cancer models [10, 41, 42]. Generally, synthetic scaffolds are mechanically stronger, 
but usually lack bioligands present in natural matrices. Therefore, in order to enhance 
the biomimetic function synthetic scaffolds have to be modified with peptides derived 
from proteins. Conjugation of specific adhesion peptides such as the integrin-binding 
motif RGD (Arg–Gly–Asp) gives an opportunity to adequately control the cell adhesion, 
integrin activation [57] and allows for studying the role of specific ligands in the process 
of cancer vascularization. Depending on the ligand conjugation method and scaffold 
properties, synthetic matrices enable for the decoupling of stiffness and adhesive ligand 
concentration [58], which is challenging to achieve in natural matrices due to the 
stiffness-concentration correlation. A similar issue concerns degradability of natural 
scaffolds due to the activity of cell secreted and cell-surface proteases. On the contrary, 
degradability of the synthetic scaffolds can be user-controlled and manipulated to 
achieve stability over desired periods of time. The degradation of synthetic scaffolds can 
be gained by incorporation of specific matrix metalloproteinase (MMP) sites or specific 
chemical groups [59]. Moreover, synthetic scaffolds offer various ways of growth factor 
delivery (entrapment, covalent, affinity based) to direct the cell fate (reviewed in [60]). 
However, both natural and synthetic scaffolds have one equally limiting factor - very 
high water content (above 90%), while to accurately mimic a tumor microenvironment 
much denser scaffolds need to be used to achieve physiologically significant diffusion of 
anti-cancer compounds [61]. Overall, synthetic scaffolds would allow for building more 
appropriate models to study cancer vascularization in vitro by providing structural 
integrity, spatiotemporal presentation of signaling molecules and allowing for 
remodeling, and cell invasion.  
The first step towards this goal has been reported by Fischbach et al. who engineered a 
3D human tumor model using carcinoma cells in synthetic poly(lactide-co-glycolide) 
(PLGA) scaffolds to recreate in vivo tumor characteristics [50]. It revealed that cells in 
this model are less sensitive to LY294002, a PI3-kinase inhibitor and have enhanced 
malignant potential as compared to Matrigel culture, indicating that research models 
based on synthetic materials might be physiologically closer to the in vivo tumors. 
However, this model was based on carcinoma monoculture lacking vascular 
 component. Nevertheless, it gave a new direction to cancer research and it is a good 
start toward the use of synthetic scaffolds to develop improved 3D models of tissue 
engineered tumor angiogenesis for anti-cancer therapy. 
3 PLATFORM DESIGN 
Although processes of angiogenesis and tumor morphogenesis have been studied 
intensively in the 3D tissue engineered setup, conjunctional models investigating the 3D 
tumor angiogenesis and cancer-EC interactions are still a scarcity. Within these 
approaches there is a strong trend leading from static toward dynamic cell cultures 
based on microfluidics in order to address the physiological function of blood vessels 
and delivery route for anti-cancer compounds (Figure 2).  
 
 Figure 2. 3D tissue engineered approaches addressing tumor vascularization. For 
simplicity, other cell types apart from cancer and endothelial were not included in the 
drawings. Numbers in the brackets represent literature sources cited in the text. 
3.1 STATIC CULTURES 
Recently, several research groups reported their efforts to recapitulate the in vivo 
environment supporting tumor formation and quantitatively evaluate therapeutic 
response [10, 25, 50, 51]. The utilized approaches range from simple cancer cell 
spheroids to models comprising of several cell types as reviewed recently by Infanger 
and colleagues [62]. They assessed tumor formation by embedding cancer cell 
suspension or preformed multicellular spheroids in ECM-derived 3D matrices of various 
compositions. However, only few of the models included the aspect of angiogenesis and 
validation of anti-cancer compounds.  
3.1.1. SUSPENSION CULTURE 
The 3D tissue engineering approach was introduced to cancer research by Janvier et al. 
who developed a sandwich model in order to study prostate cancer induced 
angiogenesis in vitro [63]. This assay utilized collagen embedded human foreskin 
fibroblasts and human PC-3 prostate adenocarcinoma planted in a fibrin gel containing 
human umbilical vein endothelial cells (HUVECs). The culture was recorded for up to 28 
days and demonstrated enhanced HUVEC morphogenesis and tube formation upon tri-
culture with both fibroblasts and cancer cells. PC-3 cells did not support angiogenesis 
as co-culture of ECs with PC-3 cells alone resulted in EC death, indicating that tube 
formation was fibroblast-dependent. Moreover, an invasive character of cancer cells 
and fibroblasts at the collagen/fibrin gel interface was observed. This novel approach in 
cancer research demonstrated that stromal cells play an important role in cancer 
angiogenesis and invasiveness. It also manifested the usefulness of 3D tissue 
engineered methods in the studies of neovascularization. Of importance, authors 
reported significant fibrin scaffold degradation and collagen scaffold shrinking during the 
experiment. This suggested that natural scaffolds may not be suitable for tong term 
experiments due to the lack of mechanical stability which could affect drug testing 
outcomes. 
 A similar sandwich design has been recently utilized by Nyga et al. to develop a 
collagen-based 3D tissue-engineered model of cancer angiogenesis mimicking colon 
cancer [61]. However, in order to faithfully address the architecture of cancer tissue with 
dense hypoxic core and loose surrounding stroma, the collagen matrix containing HT29 
human colon adenocarcinoma cells was compressed using a partial plastic 
compression, thus resulting in a six-fold increase in collagen density. This high-density 
collagen mimicking hypoxic tumor core was surrounded by a non-compressed gel 
containing HUVECs and the colon fibroblast cell line CF56. Over a time frame of 21 
days, core cancer cells developed into a hypoxic tumor mass, while ECs migrated to the 
outer part of the construct. However, vascular tube formation was not registered even in 
the presence of a hypoxic gradient and VEGF release from the tumor core. Moreover, 
when seeded with fibroblasts, shrinking of the collagen scaffolds occurred subsequently 
resulting in stratification of collagen layers. 
In another report, breast luminal and myoepithelial cells were embedded in a 3D 
Matrigel scaffold to study the effects of ECs on the growth and differentiation of human 
breast epithelial cells [64]. ECs stimulated the proliferation and cloning efficiency of 
normal (MCF10A and D382) and malignant (MCF7, T47-D and MDA-MB-231) breast 
epithelial cells via soluble factors. However, in this model ECs remained round and 
quiescent during the whole duration of the experiment, and did not form any vascular 
structures. Consequently, the assay did not allow for observation of a direct endothelial-
epithelial cell-cell interaction, and thus could benefit from further improvement.  
Collagen scaffolds were also used in another 3D model to study angiogenesis initiated 
by oral squamous carcinoma cells (OSCC-3) [47]. In this setup, ECs were seeded on 
top of the collagen cancer cell-containing gel as a confluent monolayer. Upon 3 days of 
culture, ECs invaded the collagen matrix directing towards the cancer cells, which 
suggested cancer-induced chemoattraction. Recently, this approach has been adapted 
to the bi-layered bioengineered tumor angiogenesis model. This method utilized 
telomerase-immortalized human microvascular ECs cultured as an endothelium on the 
surface of an acellular collagen I hydrogel, under which MDA-MB-231 or MCF7 cells 
were cultured in a separate collagen I gel [65]. This model confirmed that MDA-MB-231 
cells, but not MCF7 cells, induced EC proliferation and invasion into the collagen layer 
 resulting in the formation of complex capillary-like tubular network characterized with 
lumen and anastomosis. The additional acellular layer of collagen between the ECs and 
cancer cells was the rate-limiting step in regulating invasive sprouting as the degree of 
sprouting inversely correlated with the increasing matrix concentration. Moreover, the 
long time necessary for EC tubular networks to develop (7 days) suggested that 
additional crosstalk between the tumor and ECs is necessary to encourage angiogenic 
sprouting. 
3D static suspension assays have demonstrated the feasibility of analyzing crosstalk 
between tumor cells and ECs, thus indicating valuable opportunities for drug testing.  
The potential of 3D static suspension assays for this purpose, however, has not yet 
been explored.  
3.1.2 SPHEROID CULTURE 
As discussed earlier, in contrast to conventional suspension and monolayer cultures, 
cultivation of cancer cells as spherical aggregates restores morphological and functional 
features of the original tissue [51, 66]. Similarly to an avascular tumor, cancer cells in 
spheroids proliferate slower than in monolayers building a 3D structure consisting of 
proliferating (outer layer), quiescent, and necrotic cells (center). Moreover, their 
response to drugs is significantly altered and is tumor size-dependent [50, 51]. Due to 
these resemblances, multicellular spheroids became frequently utilized in cancer 
research. 
Walther-Yohling and colleagues co-cultured human SKOV-3 ovarian carcinoma cell 
clusters with human microvascular ECs, 10T1/2 cells and myofibroblasts to evaluate the 
importance of fibroblasts for tumor invasion [67]. A thick layer of Matrigel was created in 
a well plate and allowed to polymerize. A plug of Matrigel was removed and the 
resulting space was filled with SKOV-3 cells resuspended in collagen type I solution. 
ECs and myofibroblasts were added to the medium and allowed to adhere and migrate 
around the tumor cell cluster for 48 hours. Over this time, cells on the surface migrated 
toward the tumor cluster forming tubular structures and eventually invading the cluster. 
By studying multicellular aspects of cancer vascularization this study demonstrated that 
myofibroblasts support ECs during the invasion of carcinoma cell clusters. The invasion 
could be prevented by angiogenesis inhibitors SU6668 and paclitaxel, but not by a 
 broad MMP-inhibitor indicating a potential of the assay for anti-cancer drug screening. A 
similar approach of 2.5D co-culture on the Matrigel coated-surface has been used by 
Shekhar et al. for human breast epithelial cells MCF10A, breast fibroblasts and human 
ECs [68, 69]. Although prolonged 3 week long culture resulted in the branching ductal-
alveolar morphogenesis of breast cancer cells and their pro-angiogenic invasive 
phenotype, this model is rather simple in its 2D design and does not fully represent the 
tumor-microenvironment. Nevertheless, it allowed for the study of endothelial- and 
epithelial cell-specific factors that are important for ductal-alveolar morphogenesis, 
angiogenesis, and progression to malignancy.  
Spheroid culture was also utilized by Correa de Sampaio et al. who aimed to reproduce 
the early stages of tumor angiogenesis by culturing preformed spheroids consisting of 
ECs, fibroblasts and breast cancer tumor cell line MDA-MB-231 in collagen I gels [70]. 
The MDA-MB-231 breast cancer cells induced formation of capillary-like sprouts within 
2 days. The sprouts were responsive to the known anti-angiogenic agents such as 
galardin (GM6001), the broad spectrum inhibitor of metalloproteinases, but not to 
Thalidomide or Endostatin. Yet again, this report showed that the stromal cells support 
EC invasion during angiogenesis by expression of membrane-bound proteases 
indicating the need to include the stromal cells in the preclinical drug testing models.   
A similar approach has recently been utilized by Seano et al. who developed a 3D 
assay based on arterial explants from human umbilical cords and LNCaP prostate 
carcinoma spheroids embedded in Matrigel [71]. Gross blood vessel fragments provided 
the native source of cells (endothelial and non-endothelial cells) and more faithfully 
reproduced the in vivo conditions at which angiogenic sprouting occurs. Tumor clusters 
stimulated microvessel outgrowth in the absence of exogenous growth factors after 20-
25 days of co-culture. Occasional contact of EC and cancer cells was observed, 
however this aspect was not investigated. The assay was shown to be suitable for 
testing anti-cancer drugs such as Sunitinib, SU5416, PI-103, Combretastatin and 
lentiviral-mediated RNA interference, demonstrating higher sensitivity to angiogenic 
inhibitors compared with other assays such as mouse aortic ring or cell culture. 
Importantly, authors focused their efforts to develop a robust computer assisted image 
 analysis strategy of angiogenic response, which is challenging and often missing in the 
3D assays.  
To overcome the persisting limitations of ECM-derived matrices, our group has 
developed semi-synthetic starPEG-heparin hydrogels as a tool for tissue engineering 
applications [58]. The hydrogels are composed of star-shaped poly(ethylene glycol) 
(PEG) and the glycosaminoglycan heparin, crosslinked via cytocompatible Michael 
addition chemistry [72]. Our system uniquely offers control over the cellular 
microenvironment allowing for the decoupled variation of mechanical properties and 
biomolecular functionalization with growth factors, adhesion ligands, and degradable 
peptide sequences. Of importance, the starPEG-heparin hydrogels can bind and store 
several growth factors simultaneously [59, 73, 74], thus resembling ECM and being 
particularly useful for angiogenesis and cancer studies where growth factors play a 
major role. Recently, starPEG-heparin hydrogels have been utilized to develop a 3D in 
vitro model of tumor angiogenesis (Figure 3) [53]. This new model provides the 
opportunity to study the processes of heterotypic tumor-EC interactions for the first time 
in a thoroughly defined synthetic 3D matrix and recapitulates the events of tumor 
invasion by capillary sprouts. This method enables the development of both mature 
tumor spheroids and lumenized, multicellular endothelial capillaries within a short time 
(12 days). Due to the transparency and stability of the synthetic hydrogel matrix the 
method is suitable for analysis with long- and short-term optical means, both light and 
fluorescence based. Yet, the system needs to be validated as an anti-cancer screening 
platform. Future research will aim at extending the model by further increasing cellular 
complexity with respect to the choice of stromal cells, by evaluating other tumor types 
and by incorporation of endothelial network perfusion.  
 
  
Figure 3. Hepatocarcinoma (HepG2) cells cultured with HUVECs in a starPEG-heparin 
hydrogel. Functionalization of the hydrogel allows for investigating the effect of 
incorporated growth factors and integrin-binding peptides on tumor formation and 
angiogenesis in 3D. The images show a tumor spheroid (HepG2) surrounded by an 
endothelial capillary network (HUVEC). (A) Light microscopy image. White arrows point 
at endothelial capillary sprouts growing in the close proximity of tumor spheroid. (B) 3D 
confocal microscopy image of in vitro tumor vascularization (GREEN – CD31, RED – F-
ACTIN). 
3.2 DYNAMIC CULTURES 
Shear forces and blood flow are important for the vascularization process and 
maintenance of the newly developed vascular sprouts [75]. Moreover, the circulatory 
system is a common delivery route for anti-cancer compounds. Therefore, there is a 
visible trend in tissue engineering field to address the dynamic aspects of physiological 
processes such as flow, stretching and diffusion into the model design [76]. Fluid flow 
delivering oxygen and nutrients can be achieved by introduction of microfluidic channels 
into the tissue-engineered scaffold. Microfluidic devices have been shown to mimic the 
complex in vivo microenvironment better than conventional in vitro assays by allowing 
for controlled mass transport and spatiotemporal presentation of soluble factors, and 
enabled real-time monitoring of homotypic or heterotypic cellular interactions [15, 77]. 
Accordingly, Rylander’s research group recently presented a microfluidic adaptation of 
previously developed static cultures [65] in order to determine to what extent the shear 
forces generated by fluid flow will affect endothelial organization or paracrine signaling 
during tumor angiogenesis [76]. The model consisted of a single central microchannel 
 seeded with ECs and surrounded by collagen I scaffold containing MDA-MB-231 cells. 
The setup aimed to resemble a single neovessel through which tumor-relevant 
hydrodynamic stresses are introduced. In spite of the short 3-day duration of the 
experiment, it demonstrated that tumor cells significantly increase expression of pro-
angiogenic genes in response to co-culture with ECs under flow conditions. 
Nevertheless, no EC invasion into the collagen scaffold has been shown. One of the 
reasons for this could be the very high concentration (8 mg/ml) of collagen used to 
create the channel as compared to concentrations used in static cultures (0.25 mg/ml). 
The high concentration of matrix enables the scaffold stability and allows for 
microfabrication, but at the same time may significantly interfere with the diffusion of 
soluble molecules and restrict the migration, and invasion of both endothelial and 
cancer cells, subsequently affecting the studied processes. 
Another microfluidic system has been developed by George and coworkers aiming at 
efficient and accurate drug and toxicity screening for anti-cancer drugs [78]. In this 
model, endothelial colony-forming cell (ECFC)-derived ECs embedded in fibrin or 
collagen type I matrices form a continuous network of perfused microvessels in the 
presence of SW620 colorectal cancer cells. Furthermore, the capillary network and 
tumor spheroids develop in periods of 10 to 20 days, and can be continuously 
monitored by means of non-invasive and nondestructive optical techniques. 
Additionally, to increase the physiological relevance, the system can incorporate stromal 
cells (normal human lung fibroblasts) [18] or iPS-derived cardiac muscle spheroids [78]. 
Further development of this model focused on anastomosis of the EC network with 
microfluidic ports for initial testing of anti-tumor drugs. 
The microfluidic approach for co-culture combining 3D and 2D culture has been also 
presented by Kamm et al. [79, 80] as an extension of the previously developed 
vasculomimetic device [21]. It comprises of collagen type I hydrogel containing 
chambers located between surface-accessible microchannels spaced <1 mm apart. It 
enables observation of spatial-temporal cell-cell and cell-ECM communication. Different 
cell types such as human microvascular ECs and MTLn3  breast cancer cells or U87MG 
human glioblastoma cell line growing as a monolayer on the hydrogel separated 
channel walls were co cultured for 3 days. Both reports showed simultaneous cancer 
 and EC invasion. In contrast to MTLn3 cells, U87MG cells did not induce EC migration. 
Moreover, when looking at cancer cell invasion, U87MG cells showed faster migration 
into the scaffolds than MTLn3 cells. However, the collagen preparation procedure had a 
significant influence on the characteristics of cell migration. Depending on the pH and 
stiffness of the matrix, different phenotypes of cell migration were observed varying 
between sheet-like invasion and formation of 3D tube-like structures. 
Recently, a novel 3D engineered tumor model has been developed by Moll and 
colleagues to study malignant peripheral nerve sheath tumors (MPNSTs) [81]. The 
model was established with decellularized porcine jejunal segment reseeded with 
primary fibroblasts and the S462 tumor cell line on apical side, and microvascular ECs 
on the basolateral side. The cell-seeded scaffold was subsequently placed in a flow 
bioreactor system that exposed the cells to shear stress for 14 days. After that time the 
tissue was analyzed by performing histology, in order to specifically distinguish between 
different cell populations in the tissue. However, more detailed analysis focusing on the 
angiogenesis of the cancer tissue was not presented. Utilization of decellularized 
scaffolds has certain advantages such as preserved blood vessel structures, which can 
be reseeded with ECs and preserved, and structured extracellular components, which 
ensure the adhesion of the cells and facilitate tissue differentiation. Further work in this 
field will certainly bring more solutions to improve such models both in term of design 
and analysis. 
Overall, the dynamic models of 3D tumor angiogenesis are able to recapitulate the 
basic vascular unit – capillary structures, and to some extent tumor growth. Yet, they 
are still in the early development phase, and thus drug delivery has not been 
demonstrated in any of the described models.  
Summarizing, independent from the design, collagen I matrix is predominantly used for 
the 3D tissue engineered models of tumor angiogenesis. Currently, only one 3D tumor 
angiogenesis model has been based on a synthetic starPEG-heparin hydrogel [53]. 
Apart from collagen, there have been few applications of Matrigel, however due to 
various drawbacks Matrigel seems to be not compatible with 3D angiogenic research. 
First of all, Matrigel composition is not fully known and varies from batch to batch, thus 
affecting cellular response. Especially, high content of various growth factors is of 
 concern when it comes to angiogenesis and cancer research. Moreover, as potent as 
Matrigel is to induce endothelial tube formation in 3D [82], it has the opposite effect 
when EC are directly embedded in Matrigel as they remain round and acquire a silent 
phenotype [64]. On the other hand, Matrigel is a stimulating environment for cancer 
morphogenesis [83] which justifies its application in cancer research. Nevertheless, 
when it comes to tissue engineering, collagen type I is the primary choice of most 
scientists as it has defined composition and additionally allows for variation in 
mechanical properties simply by changing the concentration of protein. However, many 
reports have stated the difficulties with preserving the shape of cell-containing 
constructs over the culture time [61, 63]. But yet, collagen shrinking upon fibroblast 
seeding may be also beneficial in some cases, as it increases the scaffold density 
towards the desired in vivo condition by mimicking cancer core mass [61]. Moreover, 
collagen allows for microfabrication and upon processing is suitable for microfluidic 
application in dynamic models [76]. However, the collagen microchannels easily 
collapse or deform during the handling, even detaching from the microfluidic device [84]. 
Overall, the issue of natural scaffold stiffness and density remains under investigation, 
and it has to be well-considered in each newly developed 3D model.  
4 THE IDEAL MODEL 
 
Developing advanced 3D vascularized tumor models is a challenging aim. In cancer 
research, 3D models offer the obvious advantage of more native, physiologically 
relevant  environments which could provide better predictive power for the potential in 
vivo response to targeted anti-cancer or anti-angiogenic therapeutics. Moreover, the 
effect of the drug on multiple co-existing cell types can be studied simultaneously during 
pathological processes such as tumor vascularization or invasion. Nevertheless, the 
matrix type must be carefully evaluated in terms of assay compatibility as matrix 
parameters such as porosity and affinity can affect the drug diffusion and its interaction 
with the cells [85, 86]. Another obstacle concerns the stability of the 3D matrices which 
often degrade before the desired cellular processes are completed [63]. Thus, it is 
difficult to translate them into high throughput platforms required for testing anti-cancer 
 compounds. Moreover, 3D models are difficult to evaluate, as the development of 
methods for their analysis is lagging behind. Therefore, as shown in section 3, the 
existing 3D tumor angiogenesis models are mostly descriptive and rarely include the 
validation of anti-cancer compounds. Additionally, the 3D models are often too 
expensive due to the combination of high costs of 3D matrices and labor time. These 
issues should be addressed by the next generation of 3D tumor angiogenesis models. 
 
Over the past decade we have been continuously improving by developing new, more 
sophisticated models of tumor angiogenesis. However, despite all efforts an ideal model 
was not established yet. To achieve this goal we still have to overcome various 
technical challenges and learn how to translate the knowledge, which we gain from the 
life sciences, to the tissue engineering field. 
The ideal model of tumor angiogenesis should recapitulate the physiological 
environment of tumors while enabling control over the physical, chemical and biological 
parameters of the 3D scaffold. It should allow for real-time observation of the changes 
undergoing in the tumor microenvironment during vascularization such as cell 
proliferation, central hypoxia, compartment invasion and new vessel formation, and 
continuous monitoring of cell responses to the administered drugs. To achieve that, 
various aspects have to be addressed.  
4.1 MATERIALS 
Due to the fact that there are qualitative and quantitative differences between different 
cancer types in terms of stromal content [5], building an universal model of tumor 
angiogenesis is not possible. Moreover, tumor stroma composition undergoes changes 
during the course of tumor progression from the fibrin-like to collagenous scar-like. 
Therefore, the choice of a material to engineer a new model of cancer angiogenesis 
should be carefully considered beforehand to faithfully resemble the specific cancer 
type microenvironment and at the same time to provide a suitable environment for 
angiogenic processes. As shown in section 3, the majority of reported 3D models 
utilized collagen type I. Therefore, application of other natural materials such as 
hyaluronic acid, silk and synthetic scaffolds, which have been utilized in a variety of 
vascular biomimetic assays [19, 20], remains yet to be explored. The synthetic scaffolds 
 offer endless possibilities to create specific tumorigenic environments based on the 
controlled composition, arrangement, degradability and stiffness [50]. Their 
implementation in the next generation of 3D models will open a new window in cancer 
angiogenesis research.  
4.2 CELLS 
The cancer microenvironment comprises several cell types, which vary depending on 
the specific cancer type. Ideally, all of the cell types should be included in the model as 
they influence angiogenic processes. However, the co-culture of many cell types is very 
challenging and often not feasible due to the many arising issues such as optimal 
medium composition, cell differentiation, varying growth rates. For the sake of simplicity, 
most of the existing 3D models utilized only cancer cells and ECs [47, 64, 65]. However, 
increasing number of reports indicates that stromal fibroblasts regulate cancer 
invasiveness and angiogenesis, thus pointing out the necessity of fibroblast 
incorporation into the 3D models of cancer angiogenesis [68-70]. In the future, 
implementation of other cell types such as inflammatory cells should be addressed to 
determine their contribution to tumor angiogenesis. Moreover, apart from the cell type 
also the cell source should be well-considered. For instance, many of the studies utilize 
easily available HUVECs instead of organ-specific ECs. However, ECs derived from 
different tissues vary in terms of morphology, marker expression and metabolic 
properties [87]. Moreover, sporadic mutations shared with the parent tumors were 
recognized in angiogenic endothelium [88], thus indicating that cell source should be 
carefully considered before designing a new model [89]. Of note, the majority of 3D 
models utilize immortalized cell lines in culture, which do not contain important tumor 
stem cells or circulating tumor cells [90, 91]. Therefore it is also important to consider 
the use of isolated primary cancer cells from patient samples to study their growth and 
maintenance within the 3D models. Using patients’ own cells for personalized drug 
testing would be the final aim in order to enhance the prognostic capacity of the model 
[92].  
 
 
 4.3 ARCHITECTURE 
A solid tumor has an organized structure composed of parenchyma (neoplastic cells) 
surrounded by stroma [2]. The cancer architecture depends on the cancer type and its 
progression stage. When modeling the specific type of cancer, its in vivo architecture 
should be recapitulated by a precise spatial cell and matrix arrangement stimulating 
cell-cell and cell-ECM interactions. Thus, the future models of cancer angiogenesis 
should be engineered based on a solid clinical knowledge. The majority of the current 
methods utilize random cell seeding in the matrix. However, spatial arrangement of the 
cells up to desired architecture could be achieved by means of 3D micropatterning, 
lithography and microprinting [92]. Utilization of these approaches will lead to user-
defined control of the distance and type of interaction between different cell populations, 
along with spatiotemporal delivery of biochemical and biophysical stimuli [77]. 
5.4 CULTURE CONDITIONS 
The majority of 3D cancer angiogenesis models are also based on static culture. 
However, recent technical advancement allowed for engineering of dynamic microfluidic 
models which can be applied to cancer research. Ideally, the 3D engineered model to 
study tumor angiogenesis should include the dynamic component to mimic the blood 
flow as ECs in vivo are continuously exposed to shear stress and interstitial flow [84]. 
Moreover, the circulatory system is a common route for delivery of anti-cancer drugs 
and interstitial flow allows for generation of gradients of soluble factors [84]. Though, 
administration of soluble factors such as growth factors remains highly discussed in the 
field of cancer angiogenesis. On one side, activation of angiogenesis requires the 
activation of ECs by a VEGF gradient, thus growth factors such as VEGF are frequently 
used to model cancer angiogenesis. However, their use in co-culture may interfere with 
other cell types included in the model leading to increased proliferation and 
differentiation. Ideally, a 3D engineered model should create and maintain the intrinsic 
growth factor gradients generated by cancer cell mass without any external additives 
such as medium supplements or recombinant growth factors. This could be achieved by 
introduction of proteoglycans such as heparin sulfate or heparin to the engineered 
scaffolds, as they are known to have high affinity toward variety of growth factors [88]. 
Another issue concerns the maintenance of cell viability in the long-term 3D cell culture 
 models. High cell densities require the development of new devices to overcome the 
issues of insufficient oxygenation or accumulation of metabolic wastes which can affect 
the outcome of drug testing and mislead the results.  
4.5 ANALYSIS 
Analysis of most of the tissue engineered models remains purely descriptive and is 
based on conventional microscopy techniques such as confocal fluorescence 
microscopy [12]. Thus, further innovations are required to derive more quantitative data 
out of conducted experiments allowing for statistical analysis. As microscopy will remain 
the major analysis route of tissue engineered constructs technical advancement in high 
resolution 4D microscopy is needed to allow detailed registration of angiogenic events 
in the cancer microenvironment. The possibility of dynamic observation of tumor cells 
that recruit, interact, and stimulate the growth of new vascular structures can greatly 
advance our understanding of tumor-driven angiogenesis. Analogically, automatic 
analysis of data derived from 3D and 4D microscopy has to be developed to avoid bias 
and to simplify, and accelerate the time-consuming analysis process. However, the 
adequate registration of angiogenic events in the 3D tumor engineered models will not 
be possible without the generation of stable fluorescent protein expressing cell lines 
both of cancer, endothelial and other stromal cells as currently used cell trackers lack 
stability and often result in cytotoxicity. Finally, more effort should be directed toward the 
development of novel and more sensitive analysis methods focusing on the molecular 
cell biology of cancer angiogenesis, which would in turn allow for a more adequate 
analysis of anti-cancer therapeutics. 
4.6 APPLICATIONS 
The development of an in vitro cell culture model which mimics the microenvironment 
and tumor progression in situ is a highly important mission. The outcome will result in 
new methods to study the biology and pathogenesis of a variety of tumor forms and 
allow for accelerating the development of targeted anti-cancer compounds. Advances in 
3D modeling will allow for an opportunity to gain understanding of how the 
microenvironment signals and initiates tumor formation and angiogenesis, a process still 
relatively unknown. Furthermore, a 3D model provides the opportunity for patient drug 
 screening, and the development of cancer therapeutics which target not only the tumor 
cells but also their surrounding microenvironment. 3D culture systems could also 
complement or eventually dispel the need for expensive animal models during pre-
clinical drug development, which can still not fully mimic tumor progression in humans. 
5 CONCLUSIONS 
Significant progress has been made in tissue engineering field in the past decade, 
which has enabled the development of novel assays to study tumor angiogenesis under 
well-defined biochemical and biophysical conditions. The ultimate aim of these assays 
is to improve our understanding of cancer progression and revolutionize the cancer field 
by providing innovative tools to study cancer vascularization using pathologically 
significant culture conditions. However, the 3D models of tumor angiogenesis are still 
too simplistic in terms of cellular and acellular components, thus not being fully able to 
mimic the heterogeneous tumor microenvironment. To improve the current models and 
overcome their limitations numerous challenges need to be addressed by future studies. 
The new generation of 3D models should put more attention toward physiological 
accuracy in order to generate valid conclusions. Thus, a closer collaboration of tissue 
engineers and biologists is required to provide new culture platforms to explore cancer 
vascularization and improve the efficiency of anti-cancer drug development. 
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